Bone News and Research

RSS

EffRx submits EX101 NDA for osteoporosis treatment to FDA

EffRx Pharmaceuticals SA, a Lausanne, Switzerland based drug delivery company announces the NDA submission of the company's lead project to the US Food and Drug Administration.

10 Jan 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

HHS and EPA make new announcements on fluoride based on up to date scientific data

The U.S. Department of Health and Human Services (HHS) and the U.S. Environmental Protection Agency (EPA) today are announcing important steps to ensure that standards and guidelines on fluoride in drinking water continue to provide the maximum protection to the American people to support good dental health, especially in children.

10 Jan 2011

Single cellular crisis shatters chromosomes in cancer causation

Remarkable new research overthrows the conventional view that cancer always develops in a steady, stepwise progression. It shows that in some cancers, the genome can be shattered into hundreds of fragments in a single cellular catastrophe, wreaking mutation on a massive scale.

7 Jan 2011

Chromosome shattering seen in two to three percent of all cancers

Most of the time cancer seems to creep up gradually over time; cells become premalignant, then increasingly abnormal before they become cancerous. But sometimes cancers seem to pop up as if out of nowhere. Now, researchers reporting in the January 7th issue of the journal Cell, a Cell Press publication, have new evidence to explain how that can happen.

7 Jan 2011

IDSA releases MRSA treatment guidelines

Physicians now have help in their battle against methicillin resistant Staphylococcus aureus (MRSA), a potentially deadly infection that initially was limited to hospitals and health care facilities but has become a growing problem in healthy children and adults. The Infectious Diseases Society of America (IDSA) has released its first guidelines for the treatment of increasingly common MRSA infections.

7 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Robo4 molecule may improve bone marrow transplants: Study

Researchers at the University of California, Santa Cruz, have identified a key molecule for establishing blood stem cells in their niche within the bone marrow. The findings, reported in the January issue of Cell Stem Cell, may lead to improvements in the safety and efficiency of bone marrow transplants.

7 Jan 2011

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy, a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.

6 Jan 2011

RadNet completes acquisition of Brooklyn and Orchard Park imaging centers

RadNet, a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 200 fully-owned and operated outpatient imaging centers, today reported it has completed the acquisition from Presgar Imaging and affiliated entities of imaging centers in Brooklyn and Orchard Park, New York for cash consideration of $2.2 million plus the assumption of approximately $700,000 of debt.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Researchers regenerate complete shoulder joint surfaces using patient's own cells

Artificial joint replacements can drastically change a patient's quality of life. Painful, arthritic knees, shoulders and hips can be replaced with state-of-the-art metal or ceramic implants, eliminating pain and giving a person a new lease on life.

6 Jan 2011

Breakthrough in MRI allows brain scans more than seven times faster

An international team of physicists and neuroscientists has reported a breakthrough in magnetic resonance imaging that allows brain scans more than seven times faster than currently possible.

6 Jan 2011

ODS enters license agreement with Enox Biopharma to develop novel treatment for periodontal disease

Enox Biopharma, a leader in the development of innovative solutions for infections associated with medical devices, and Ortho Dental Solutions LTD today announced an execution of an exclusive royalty bearing license agreement under which Enox Biopharma shall grant Ortho Dental Solutions LTD rights to patent application and knowhow for use in developing novel therapies limited in use for dental and gum diseases.

6 Jan 2011

Researchers investigate umbilical cord blood stem cells for traumatic brain injury in children

The University of Texas Health Science Center at Houston has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child's own umbilical cord blood stem cells for traumatic brain injury in children.

6 Jan 2011

DJO Incorporated announces acquisition of Elastic Therapy

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the acquisition of Elastic Therapy, Inc. The acquisition closed yesterday, January 4, 2011.

6 Jan 2011

$Special knowledge of growth physiology needed to treat fractures in children$

Special knowledge of growth physiology needed to treat fractures in children

Treating fractures in children requires special knowledge of growth physiology. Incorrect treatment of bone fractures in child and adolescent patients is less often caused by technical deficiencies than by a misjudgment of the special conditions in this age group.

5 Jan 2011

Bone News and Research

EffRx submits EX101 NDA for osteoporosis treatment to FDA

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

HHS and EPA make new announcements on fluoride based on up to date scientific data

Single cellular crisis shatters chromosomes in cancer causation

Chromosome shattering seen in two to three percent of all cancers

IDSA releases MRSA treatment guidelines

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Robo4 molecule may improve bone marrow transplants: Study

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

RadNet completes acquisition of Brooklyn and Orchard Park imaging centers

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Researchers regenerate complete shoulder joint surfaces using patient's own cells

Breakthrough in MRI allows brain scans more than seven times faster

ODS enters license agreement with Enox Biopharma to develop novel treatment for periodontal disease

Researchers investigate umbilical cord blood stem cells for traumatic brain injury in children

DJO Incorporated announces acquisition of Elastic Therapy

Special knowledge of growth physiology needed to treat fractures in children

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News